Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · 21Shares Sui Staking ETF (TSUI)

21Shares Sui ETF to end CF Benchmarks license, switch to FTSE index data

Neutral Impact 2 of 5 product/contract Written later

21Shares US LLC, the sponsor of the 21Shares Sui ETF, gave CF Benchmarks notice on June 30, 2026 that it is terminating the licensing agreement for the CME CF Sui Dollar Reference Rate, effective August 31, 2026. The sponsor plans to license FTSE index data on or about August 24, 2026, as part of a broader move to a new benchmark provider. Because the benchmark is used to value the trust's shares daily and to calculate net asset value, shareholders will be affected by this change of provider.

Key points

  • Sponsor gave termination notice to CF Benchmarks on June 30, 2026, effective August 31, 2026
  • Terminated agreement covers the CME CF Sui Dollar Reference Rate, New York Variant, used to value shares and calculate NAV
  • Sponsor intends to enter a licensing agreement with FTSE International Limited on or about August 24, 2026
  • FTSE license is expected to have a one-year initial term that renews automatically

The filing

Company21Shares Sui Staking ETF (TSUI)
Form8-K, current report
Filed with the SECJul 7, 2026, 4:35 PM ET
Accession number0001213900-26-075997

Items reported: 1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.